Fresenius Medical Care AG & Co. KGaA (NYSE: FMS – Get a rating) saw its target price lowered by Societe Generale investment analysts from €61.00 ($69.32) to €57.00 ($64.77) in a research report delivered to clients and investors on Friday, Fly reports.

Other research analysts have also recently published research reports on the company. Jefferies Financial Group downgraded Fresenius Medical Care AG & Co. KGaA from a “hold” rating to an “underperform” rating and lowered its price target for the company from $32.40 to $30.30 in a report from the Friday February 11. JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a Tuesday, Nov. 9 research note. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Fresenius Medical Care AG & Co. KGaA in a Wednesday, Dec. 1 research note. HSBC began covering Fresenius Medical Care AG & Co. KGaA in a research note on Tuesday November 23. They issued a “hold” rating on the stock. Finally, Royal Bank of Canada lowered its price target on Fresenius Medical Care AG & Co. KGaA from $42.00 to $35.00 and set a “sector performance” rating on the stock in a memo. research from Wednesday, November 17. Two equity research analysts gave the stock a sell rating, eight gave the stock a hold rating and four gave the stock a buy rating. According to data from MarketBeat.com, Fresenius Medical Care AG & Co. KGaA has a consensus rating of “Hold” and an average target price of $39.46.

Shares of Share Fresenius Medical Care AG & Co. KGaA traded at $0.91 on Friday, reaching $32.70. 440,004 shares of the company were traded, with an average volume of 468,015. The stock has a fifty-day moving average price of $33.05 and a 200-day moving average price of $34.38. The company has a market cap of $19.16 billion, a price-to-earnings ratio of 17.49, a growth price-to-earnings ratio of 15.72, and a beta of 1.19. The company has a current ratio of 1.07, a quick ratio of 0.78 and a debt ratio of 0.49. Fresenius Medical Care AG & Co. KGaA has a fifty-two week minimum of $29.71 and a fifty-two week maximum of $42.45.

Several institutional investors and hedge funds have recently increased or reduced their stake in FMS. FMR LLC increased its position in shares of Fresenius Medical Care AG & Co. KGaA by 40.5% during the 2nd quarter. FMR LLC now owns 29,152 shares of the company worth $1,212,000 after purchasing an additional 8,397 shares in the last quarter. Pzena Investment Management LLC acquired a new equity position in Fresenius Medical Care AG & Co. KGaA during Q3 for a value of approximately $224,080,000. Nuveen Asset Management LLC increased its position in shares of Fresenius Medical Care AG & Co. KGaA by 3.5% during the 2nd quarter. Nuveen Asset Management LLC now owns 520,440 shares of the company worth $21,635,000 after purchasing an additional 17,777 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Fresenius Medical Care AG & Co. KGaA by 200.1% during the second quarter. JPMorgan Chase & Co. now owns 6,488 shares of the company worth $270,000 after buying 4,326 more shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership acquired a new equity position in Fresenius Medical Care AG & Co. KGaA during Q3 for a value of approximately $6,977,000. Institutional investors hold 4.89% of the company’s shares.

About Fresenius Medical Care AG & Co. KGaA (Get a rating)

Fresenius Medical Care AG & Co KGaA is committed to providing products and services to patients with chronic kidney disease. It also develops and manufactures a variety of healthcare products, including dialysis and non-dialysis products. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.

Read more

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in Fresenius Medical Care AG & Co. KGaA right now?

Before you consider Fresenius Medical Care AG & Co. KGaA, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes a turn… and Fresenius Medical Care AG & Co. KGaA was not on the list.

While Fresenius Medical Care AG & Co. KGaA currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here